拉氧头孢所致凝血功能障碍：发病率及危险因素
Latamoxef-induced coagulation disorders: Incidence and risk factors.
作者信息
Cai Yan, Zhang Minggang, Wang Yan, Wang Na, Zhang Li, Zhang Kanghuai
机构信息
Department of Pharmacy, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Blood Transfusion, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
出版信息
J Clin Pharm Ther. 2021 Oct;46(5):1382-1386. doi: 10.1111/jcpt.13435. Epub 2021 Jun 10.
WHAT IS KNOWN AND OBJECTIVE
To observe the effect of latamoxef on coagulation function and to analyse its risk factors.
METHODS
A retrospective cohort study was performed to compare patients receiving latamoxef versus those treated with ceftazidime. Baseline characteristics and coagulation parameters were recorded and analysed to explore whether treatment with latamoxef increased the risks of coagulation disorders and bleeding.
RESULTS AND DISCUSSION
A total number of 162 patients receiving latamoxef and 93 patients receiving ceftazidime were included. Haemorrhagic events were similar between groups, but patients receiving latamoxef had a higher risk of coagulation disorders compared to those receiving ceftazidime. Multivariate analysis revealed that the exposure of antibiotics, especially the cumulative defined daily doses (DDDs), and the nutrition risk may be the predictors of coagulation disorders.
WHAT IS NEW AND CONCLUSION
Latamoxef might induce coagulation disorders. Cumulative DDDs and the nutrition risk were linked with coagulation disorders.
已知信息与目的
观察拉氧头孢对凝血功能的影响并分析其危险因素。
方法
进行一项回顾性队列研究，比较接受拉氧头孢治疗的患者与接受头孢他啶治疗的患者。记录并分析基线特征和凝血参数，以探讨拉氧头孢治疗是否会增加凝血障碍和出血的风险。
结果与讨论
共纳入162例接受拉氧头孢治疗的患者和93例接受头孢他啶治疗的患者。两组间出血事件相似，但与接受头孢他啶治疗的患者相比，接受拉氧头孢治疗的患者发生凝血障碍的风险更高。多因素分析显示，抗生素暴露，尤其是累积限定日剂量（DDD）以及营养风险可能是凝血障碍的预测因素。
新发现与结论
拉氧头孢可能诱发凝血障碍。累积DDD和营养风险与凝血障碍有关。
Zotero 插件